Evgen Pharma Share Discussion Threads

[on target] 23/12/2021 15:33

Only Kingalf would attempt to make a negative of having 7 quarters cash runway and hiring decent people lol.

WAC

[kingalf] 23/12/2021 14:08

Having reviewed the latest set of accounts the following caught my attention
"The Directors estimate that the cash and cash equivalents including short-term investments and cash on deposit, held by the Group together with known receivables will be sufficient to support the current level of activities into the third quarter of calendar year 2023. They have therefore prepared the financial statements on a going concern basis"
If they don't pull their finger out soon, there will be a further dilution in around 15 months.
Probably why the board don't own any shares apart from the freebies.
Still, jobs for the boys / girls is clearly evident here, it's like they've employed formula one mechanics to service an Austin Allegro.

[on target] 21/12/2021 16:50

Looks like someone had a nice 865k chunk earlier - was waiting to see why the offer shot back up.

[clocktower] 21/12/2021 12:09

I expect this dog will get its day this coming year.Plenty of cash, unli9ke some.

[markth126] 21/12/2021 11:54

Drip drip,Story of my portfolio at the minute!! Kight should be weighing in down here

[nobbygnome] 15/12/2021 21:20

Well he/she only posts on EVG...

[on target] 15/12/2021 21:14

Any connection to the US-based contract manufacturer they have now ditched or are in the process or ditching?

[on target] 15/12/2021 21:13

"annuity checks" - another phrase and spelling only found the other side of the pond.

Intrigued why someone from the US would be interesting in 'dissing' this little UK company?

[mrwizard1] 15/12/2021 21:06

Don't hold your breath! BoD and management off on holiday waiting for their annuity checks.

[markth126] 15/12/2021 18:42

Wonder if we'll get an update on developments this side of Xmas.

[bchoco] 11/12/2021 13:29

Maybe we forgot but the Chinese were not making any that needed testing - brown envelopes made all testin* or efficient phases redundant while UK made had to undergo scrutiny 😳🤔 innova was thrown out from us as inefficient and unreliable...㊂0;

[dougmachin] 11/12/2021 13:08

..............

[moneymunch] 11/12/2021 09:06

Daniel Conole
Imperial College London
Research Associate in Chemical Biology
Imperial College London

Sep 2018 - Present 3 years 4 months

London, United Kingdom

I am working in Prof. Ed Tate's research group primarily on a Evgen-Imperial translational collaboration that uses chemical proteomics technology to identify the target(s) of sulforaphane and novel sulforaphane analogues in specific disease model systems. This provides understanding of sulforaphane's mechanisms of action and contributes data important for current and future clinical development of SFX-01, Evgen's phase II clinical candidate for treatment of metastatic breast cancer.

[kingalf] 10/12/2021 12:47

A cynic would argue that the bods are part of an elaborate scheme to enrich themselves at the expense of shareholders. Huw's track record as a CEO is shockingly poor, just look him up at Company house.
Still some opportunities to make a small return on these, a good entry point IMHO is around 4.81p, with a potential return of around 20%.

[on target] 09/12/2021 11:21

Anyway the RNS could have been better presented, there has clearly been a bit of a slippage (3-6 months) on the previously anticipated timescales - possibly related to FDA slowness which seems to be affecting a lot of companies at the moment. But this was already fairly evident due to the lack of newsflow this quarter.

But the strategy still seems clear enough, especially if read in conjunction with previous releases and presentations.
Pre-IND meeting with FDA now Q1 next year (was previously Q4 this) and Glioma/Glioblastoma trial starting Q2 (was previously Q1). Note: all pre-clinical work is now complete for this according to Tuesday's RNS which I think was new news.
At the same time they have been working on this new tablet formation suitable for commercial scale production for which they are intending to do a PK/PD study to look at dosages etc in similar timescales.
The other stuff seems to be ticking away in the background presumably waiting for the CBO/CMO to do something regards partners/licencees.

Still heavily cashed up to the tune of ~£10m with more due from Juvenscence down the line.

[on target] 09/12/2021 11:07

Not heard the phrase "hot mess" that mrwizard keeps repeating before so had to look it up. Appears to be US slang?

[mrwizard1] 08/12/2021 22:01

Simply stated, shareholder value has not been created since the company's inception. Major shareholders should demand a change to the board and increase involvement with management decisions. This company is run by people who think they work in "Big Pharma", not a startup. There is no sense of urgency. Perhaps, they want to continue the annuity payments. The latest "Cut & Paste" RNS made no statements about the activities of the CEO, CBO, and CMO. What are they doing? What is the strategy and what specific tactics are being employed. No need for any disclosure of proprietary information, just focus on process and activities. There were also no statements about progress by Juvenescence. Is there any? As I posted previously, a "hot mess".

[lovewinshatelosses] 08/12/2021 20:43

Have the company stated what the share price target is, and over what timeframe, in order to trigger the criteria for these free shares?

[amaretto1] 08/12/2021 16:25

Thinking of dumping the lot...Only problem is it would hurt u LTH ... half it to tupence !!

[amaretto1] 08/12/2021 16:24

All us lot buying in at placing and above ..... then along comes his mate and buys nearly 10 percent of company for near half price !!Stinks

[lovewinshatelosses] 08/12/2021 16:07

I bought some more. I must be stark, raving mad....

[markth126] 08/12/2021 14:18

It just aligns the management to shareholders better, linked to performance and share price appreciation. I'm ok with it and added 200k today!

[clocktower] 07/12/2021 08:06

Useful keeping a number of irons in the fire, so to speak, so adding is de-risking.